Jinghai Weixiang Biomaterials
AI-driven synthetic biology for bio-based materials.
About Jinghai Weixiang Biomaterials
Jinghai Weixiang Biomaterials, operating as Gwalrus Biomaterials, is a high-tech enterprise founded in 2020. The company focuses on the complete industrial-chain innovation of bio-based materials, integrating AI, synthetic biology, and material science. Gwalrus Biomaterials has developed a closed-loop system that transforms non-food biomass into polylactic acid (PLA) and its subsequent products, also incorporating recycling of PLA (rPLA). The process encompasses the conversion of biomass to lactic acid, then to lactide, and finally to PLA. This strategy positions the company as a key player in the green, low-carbon bio-manufacturing sector. The company has made significant technological advancements across its production chain. Notable breakthroughs include a "gypsum-free lactic acid technology," which resolves the environmental issue of large-scale solid waste generated in traditional lactic acid production. Other key innovations are in non-food biomass utilization and the development of next-generation industrial strains. In early 2026, Gwalrus Biomaterials secured approximately 100 million in a Series B financing round, led exclusively by Jiazhi Fund. This funding is aimed at expanding the production capacity of its large-scale base, advancing research and development of next-generation technologies, and growing its market presence. The company is also preparing for a subsequent Series B+ financing round.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 18.0/100
- Industry
- Chemicals
- Sector
- Biotechnology, Biomaterials, Core AI, Synthetic Biology, Advanced Materials, Bioplastic, DT and LS, science-based
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jan 2026 | $14M | $55M | Undisclosed | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Jinghai Weixiang Biomaterials in its local ecosystem
The Jinghai Weixiang Biomaterials office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jinghai Weixiang Biomaterials on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jinghai Weixiang Biomaterials’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







